Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Epogen
Pharma
FDA denies Akebia med, a 2nd blow to the oral anemia class
The FDA has issued a complete response letter to Akebia and Otsuka, denying their bid for approval of vadadustat to treat anemia associated with CKD.
Kevin Dunleavy
Mar 31, 2022 8:25am
AZ, FibroGen's roxadustat heart safety data dispel doubt—mostly
Nov 11, 2019 5:12am
AZ, FibroGen's roxadustat adds 2nd China nod ahead of U.S. filing
Aug 22, 2019 11:36am
The top 10 all-time biggest-selling drugs by 2024
Aug 15, 2019 11:51am
Amgen CEO scores 10% raise to $18.6M in 2018
Apr 9, 2019 10:39am
AZ, FibroGen's roxadustat nabs blockbuster China approval
Dec 18, 2018 12:00pm
